Pulmonary Vascular Thrombosis in COVID-19: Clinical and Morphological Parallels

IF 0.3 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
O. Porembskaya, V. Kravchuk, M. Galchenko, R. Deev, M. Chesnokov, A. V. Avanesyan, K. Lobastov, S. Tsaplin, L. Laberko, V. S. Ermakov, O. Pashovkina, I. Schastlivtsev, S. Sayganov
{"title":"Pulmonary Vascular Thrombosis in COVID-19: Clinical and Morphological Parallels","authors":"O. Porembskaya, V. Kravchuk, M. Galchenko, R. Deev, M. Chesnokov, A. V. Avanesyan, K. Lobastov, S. Tsaplin, L. Laberko, V. S. Ermakov, O. Pashovkina, I. Schastlivtsev, S. Sayganov","doi":"10.20996/1819-6446-2022-08-01","DOIUrl":null,"url":null,"abstract":"Aim. We aimed to study the histological and thrombotic changes in lung vessels in patients who died with COVID-19, to access the correlation between anticoagulation therapy (ACT) and thrombotic events (TE), treatment results, clinical and laboratory patients' characteristics.Material and Methods. We retrospectively analyzed treatment results of patients hospitalized with COVID-19 and lung vessel samples of the deceased patients. Dynamic changes and highest levels of D-dimer and fibrinogen were studied in its correlation with the disease severity according to SOFA score, computer tomographic (CT) results, lung, renal and hepatic dysfunction. The association between different doses of ACT and treatment results, laboratory indicators and thrombotic events was accessed. The histological lung vessels examination was performed using Martius Scarlet Blue (MSB)staining.Results. 313 patients were included in the study (61 patients died). The median age of hospitalized patients was 60 years (IQR 51-66 years). The frequency of the intravitallyconfirmed TE was 4,8%. The strong statistical association was revealed between D-dimer level and 3-4 points SOFA score, patients' mortality, oxygen support requirement, CT3-CT4 pneumonia, glomerular filtration rate and TE. There was no mortality in patients with D-dimer normal references, but in cases with three times elevation reached 13%, 48,5% - in cases with 3-6 times elevation and 64,6% - in cases with more than 6 times elevation. The strong statistical association was registered between fibrinogen and SOFA score, CT 3-4 pneumonia, patients' mortality. D-dimer and fibrinogen levels demonstrated weak correlation. There was no statistical correlation between prophylactic, intermediate and therapeutic ACT and D-dimer and fibrinogen levels, CT results, patients' mortality. MSBstaining was used in 36 deceased patients tissue samples. 1394 lung vessels were analyzed. Lung vessels thrombi persisted in samples of all 36 patients (100%). Vessels with the diameter 3,5-30 mm were thrombosed in 7%, with the diameter 0,034-0,84 mm - in 48%, with the diameter 0,85-3,4 mm - in 45%. The frequency of thrombi persisted 06 hours, 6-12 hours, 12-18hours, 18-24 hours and more than 24 hours was12%, 14%, 62%, 5% and 7% respectively.Conclusion. Thrombi of different ages from fresh to organized were observed in one third of lung vessels in all deceased patients. Lung vessels thrombosis plays an important role in pathogenesis and thanatogenesis of COVID-19. The D-dimer level correlates with lung, renal dysfunction, patients' mortality and doesn't show any correlation with ACT and can be accepted as a criterion of lung vessel thrombotic progression.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"8 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rational Pharmacotherapy in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20996/1819-6446-2022-08-01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 1

Abstract

Aim. We aimed to study the histological and thrombotic changes in lung vessels in patients who died with COVID-19, to access the correlation between anticoagulation therapy (ACT) and thrombotic events (TE), treatment results, clinical and laboratory patients' characteristics.Material and Methods. We retrospectively analyzed treatment results of patients hospitalized with COVID-19 and lung vessel samples of the deceased patients. Dynamic changes and highest levels of D-dimer and fibrinogen were studied in its correlation with the disease severity according to SOFA score, computer tomographic (CT) results, lung, renal and hepatic dysfunction. The association between different doses of ACT and treatment results, laboratory indicators and thrombotic events was accessed. The histological lung vessels examination was performed using Martius Scarlet Blue (MSB)staining.Results. 313 patients were included in the study (61 patients died). The median age of hospitalized patients was 60 years (IQR 51-66 years). The frequency of the intravitallyconfirmed TE was 4,8%. The strong statistical association was revealed between D-dimer level and 3-4 points SOFA score, patients' mortality, oxygen support requirement, CT3-CT4 pneumonia, glomerular filtration rate and TE. There was no mortality in patients with D-dimer normal references, but in cases with three times elevation reached 13%, 48,5% - in cases with 3-6 times elevation and 64,6% - in cases with more than 6 times elevation. The strong statistical association was registered between fibrinogen and SOFA score, CT 3-4 pneumonia, patients' mortality. D-dimer and fibrinogen levels demonstrated weak correlation. There was no statistical correlation between prophylactic, intermediate and therapeutic ACT and D-dimer and fibrinogen levels, CT results, patients' mortality. MSBstaining was used in 36 deceased patients tissue samples. 1394 lung vessels were analyzed. Lung vessels thrombi persisted in samples of all 36 patients (100%). Vessels with the diameter 3,5-30 mm were thrombosed in 7%, with the diameter 0,034-0,84 mm - in 48%, with the diameter 0,85-3,4 mm - in 45%. The frequency of thrombi persisted 06 hours, 6-12 hours, 12-18hours, 18-24 hours and more than 24 hours was12%, 14%, 62%, 5% and 7% respectively.Conclusion. Thrombi of different ages from fresh to organized were observed in one third of lung vessels in all deceased patients. Lung vessels thrombosis plays an important role in pathogenesis and thanatogenesis of COVID-19. The D-dimer level correlates with lung, renal dysfunction, patients' mortality and doesn't show any correlation with ACT and can be accepted as a criterion of lung vessel thrombotic progression.
COVID-19肺血管血栓形成:临床和形态学的相似之处
的目标。我们旨在研究COVID-19死亡患者肺血管的组织学和血栓形成变化,了解抗凝治疗(ACT)与血栓形成事件(TE)、治疗结果、临床和实验室患者特征的相关性。材料和方法。我们回顾性分析COVID-19住院患者的治疗结果和死亡患者的肺血管样本。根据SOFA评分、计算机断层扫描(CT)结果、肺、肾、肝功能障碍,研究d -二聚体和纤维蛋白原的动态变化及最高水平与疾病严重程度的相关性。不同剂量的ACT与治疗结果、实验室指标和血栓事件之间的关系被访问。采用马氏猩红蓝(MSB)染色进行肺血管组织学检查。313例患者纳入研究(61例死亡)。住院患者的中位年龄为60岁(IQR为51 ~ 66岁)。经静脉确认的TE发生率为4.8%。d -二聚体水平与3-4分SOFA评分、患者死亡率、氧支持需要量、CT3-CT4肺炎、肾小球滤过率、TE有较强的统计学相关性。d -二聚体正常参照物患者无死亡率,但3倍升高的患者死亡率分别为13%、48.5%(3-6倍升高)和64.6%(6倍以上升高)。纤维蛋白原与SOFA评分、CT 3-4肺炎、患者死亡率有较强的统计学相关性。d -二聚体与纤维蛋白原水平呈弱相关。预防、中间、治疗性ACT、d -二聚体及纤维蛋白原水平与CT结果、患者死亡率无统计学相关性。36例死者组织标本采用msb染色。分析了1394条肺血管。所有36例患者样本中均存在肺血管血栓(100%)。直径为3.5 - 30mm的血管血栓发生率为7%,直径为0,034-0,84 mm的血管血栓发生率为48%,直径为0,85-3,4 mm的血管血栓发生率为45%。血栓持续时间为06小时、6-12小时、12-18小时、18-24小时和超过24小时的发生率分别为12%、14%、62%、5%和7%。在所有死亡患者中,三分之一的肺血管中观察到从新鲜到有组织的不同年龄的血栓。肺血管血栓形成在COVID-19的发病和死亡发生中起重要作用。d -二聚体水平与肺功能、肾功能、患者死亡率相关,与ACT无相关性,可作为肺血管血栓形成进展的标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Rational Pharmacotherapy in Cardiology
Rational Pharmacotherapy in Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.00
自引率
50.00%
发文量
79
审稿时长
6 weeks
期刊介绍: The primary goals of the Journal are consolidation of information on scientific and practical achievements in pharmacotherapy and prevention of cardiovascular diseases and continuing education of cardiologists and internists. The scientific concept of the edition suggests the publication of information on current achievements in cardiology, the results of national and international clinical trials. The Journal publishes original articles on the results of clinical trials designed to study the effectiveness and safety of drugs, analysis of clinical practice and its compliance with national and international recommendations, expert s’ opinions on a wide range of cardiology issues, associated conditions and clinical pharmacology. There is a heading “Preventive cardiology and public health” in the Journal to stimulate research interest in this highly demanded area. Memories of the outstanding people in medicine including cardiology, which are of great interest to historians of medicine, are published in "Our Mentors” heading.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信